Quick access:

Xeris Pharmaceuticals Appoints Mark Thierer to Board of Directors

01/10/2019

Mr. Thierer has a demonstrated track record of successful financial and operational strategy through more than 30 years of experience in the healthcare industry.

Twist Bioscience Showcases New Innovation Lab at SynBioBeta 2019

01/10/2019

Innovation Lab is a program designed to translate customer needs into new, disruptive products facilitated by synthetic DNA at a scale previously unavailable.

Inscripta Launches the World’s First Benchtop Platform for Digital Genome Engineering

01/10/2019

The Onyx™ platform enables scientists to create libraries of millions of precisely engineered single cells in one experiment through a fully automated workflow.

XERIS PHARMACEUTICALS BEGINS DOSING PATIENTS IN A PHASE 2 CLINICAL TRIAL EVALUATING ITS NOVEL FIXED-RATIO CO-FORMULATION OF PRAMLINTIDE-INSULIN FOR DIABETES

19/09/2019

The XeriSol™ technology allows for simultaneous concentration and stabilization of insulin and pramlintide, which are incompatible in aqueous (water-based) formulations.

XERIS PHARMACEUTICALS RECEIVES U.S. FDA APPROVAL FOR GVOKE™ (GLUCAGON)

10/09/2019

GVOKE is the first premixed, prefilled, premeasured liquid glucagon offering ease of use for severe hypoglycemia.

KERANOVA RAISES €24M IN SECOND ROUND OF FINANCING

10/09/2019

Funds will enable company to finalize regulatory process with view to obtaining CE mark for ultra-fast robotized ophthalmology laser.

Inscripta Appoints Jim Lalonde to Lead Microbial Digital Genome Engineering Business and Portfolio Strategy

05/09/2019

Dr. Lalonde has spent more than 25 years in research and development leadership, overseeing significant advances in methods for enzyme engineering and directed evolution.

Twist Bioscience launches Long Oligos to fuel drug development, DNA data storage and gene editing research

29/07/2019

At up to 300 bases, or nucleotides, in length this is the longest commercial oligo offering by continuous chemical synthesis in the industry.

CEVA COMPLETES ACQUISITION OF IDT VETERINARY BUSINESS ASSETS, MOVING CLOSER TO ITS 2020 OBJECTIVE OF 50:50 BIO-PHARMA SPLIT

03/07/2019

Ceva and IDT have successfully completed the acquisition of IDT’s veterinary biopharmaceutical and R&D activities by Ceva.